As previously reported, Compass Point analyst Rommel Dionisio initiated coverage of Charlotte’s Web with a Buy rating and $12 price target. A longer than expected delay in the U.S. FDA issuing regulatory guidelines for the introduction of CBD-infused edibles and beverages has pressured shares, but he sees Charlotte’s Web being the best positioned company to benefit from what should be significant growth in the CBD industry for many years to come given position as a pure play with the number one brand of cannabidiol infused products in the U.S.